Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…
REGULATORY
Deregulation Panel Urges Discussions on Secondary Use of Medical Data Without Patient Consent
The government’s regulatory reform promotion council compiled its recommendation on June 1, calling for discussions on allowing the secondary use of “pseudonymized” medical data without necessarily requiring patient consent. The recommendation urges the government to swiftly upgrade laws and regulations…
To read the full story
Related Article
- JPMA Calls for Legal Framework to Facilitate Use of Pseudonymized Data
November 27, 2024
- Legal Changes Needed to Push Use of Pseudonymized Data in Drug R&D: MHLW Working Group
January 16, 2024
- MHLW to Set Up Team Dedicated to Executing Healthcare DX Timeline
June 13, 2023
- Japan Unveils Healthcare DX Timeline, Set to Drive Secondary Data Usage by Drug Makers
June 6, 2023
- Japan to Launch New Forum to Spur Secondary Use of Medical Data in Drug Discovery
May 30, 2023
- Deregulation Panel Eyes Use of Medical Data “Without Patient Consent”
May 17, 2023
REGULATORY
- Ex-Minister Takemi to Set Up Nonprofit to Bolster Pharma Innovation
December 11, 2024
- LDP Study Group Urges Health, Finance Ministers to Drop Off-Year Revisions
December 11, 2024
- PM Ishiba Elusive on Course of Off-Year Revisions: Diet Session
December 10, 2024
- Gene Therapies from Ferring, Ultragenyx in Line for Orphan Status, Moderna mRNA Drug Too
December 10, 2024
- PM Ishiba Takes Note of Opposition Party’s Plea for Scrapping Off-Year Revisions
December 9, 2024
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…